Polivy

Polivy is a cancer medicine used to treat adults with diffuse large B-cell lymphoma (DLBCL, a blood cancer affecting white blood cells): - in patients whose cancer has not been treated before. It is used in combination with rituximab, cyclophosphamide and doxorubicin (other cancer medicines) and prednisone (a corticosteroid); - in patients whose cancer has returned or has stopped responding to other treatments and who cannot have a stem cell transplantation (a procedure where the patient’s bone marrow is replaced by stem cells from a donor to form new bone marrow), Polivy is used in combination with two other cancer medicines, bendamustine and rituximab. DLBCL is rare, and Polivy was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 16 April 2018. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/eu3182013](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182013). Polivy contains the active substance polatuzumab vedotin.